It’s been 13 years since the term “precision medicine” was coined, and its promise — the ability to treat the right patient with the right medicine in the right dose at the right time — remains as compelling as ever.
But we haven’t yet fulfilled this promise. Why?
In my previous role as head of precision medicine at Novartis, I realized the biggest challenge to making precision medicine a reality was not the development of the medicines themselves, but the development — or lack thereof — of the necessary diagnostics.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in